Zhiguo Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3794046/publications.pdf

Version: 2024-02-01

687363 794594 22 982 13 19 h-index citations g-index papers 25 25 25 1496 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Profiling Analysis of Circular RNA and mRNA in Human Temporal Lobe Epilepsy with Hippocampal Sclerosis ILAE Type 1. Cellular and Molecular Neurobiology, 2022, 42, 2745-2755.	3.3	6
2	Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance. Neuro-Oncology, 2022, 24, 1113-1125.	1.2	64
3	Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients. Molecular Medicine, 2021, 27, 52.	4.4	10
4	GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma. Cancer Cell International, 2021, 21, 297.	4.1	7
5	Differential DNA Methylation Profiles in Patients with Temporal Lobe Epilepsy and Hippocampal Sclerosis ILAE Type I. Journal of Molecular Neuroscience, 2021, 71, 1951-1966.	2.3	11
6	Study of Neuronal Apoptosis ceRNA Network in Hippocampal Sclerosis of Human Temporal Lobe Epilepsy by RNA-Seq. Frontiers in Neuroscience, 2021, 15, 770627.	2.8	11
7	Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Research, 2020, 80, 499-509.	0.9	68
8	Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma. Oncolmmunology, 2019, 8, e1621677.	4.6	30
9	CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nature Communications, 2019, 10, 4016.	12.8	208
10	The MicroRNA Expression Profiles of Human Temporal Lobe Epilepsy in HS ILAE Type 1. Cellular and Molecular Neurobiology, 2019, 39, 461-470.	3.3	9
11	TMIC-49. ABROGATING CD70 EXPRESSION IN GBM RESULTS IN A REDUCED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT. Neuro-Oncology, 2019, 21, vi258-vi258.	1.2	0
12	CD70, a novel target of CAR T-cell therapy for gliomas. Neuro-Oncology, 2018, 20, 55-65.	1.2	122
13	IMMU-56. CXCR1/2 MODIFIED CARs CO-OPT RADIATION-INDUCED IL-8 FOR ENHANCED CHEMOTAXIS OF THE CAR T CELLS AND MAXIMAL ANTI-TUMOR EFFICACY. Neuro-Oncology, 2018, 20, vi134-vi134.	1.2	0
14	Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. Molecular Therapy - Oncolytics, 2018, 11, 20-38.	4.4	123
15	The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas. Frontiers in Molecular Neuroscience, 2018, 11, 82.	2.9	61
16	Targeting of microRNA-21-5p protects against seizure damage in a kainic acid-induced status epilepticus model via PTEN-mTOR. Epilepsy Research, 2018, 144, 34-42.	1.6	26
17	Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM. International Journal of Cancer, 2017, 141, 1434-1444.	5.1	70
18	CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression. Frontiers in Immunology, 2017, 8, 1451.	4.8	47

ZHIGUO LIN

#	Article	lF	CITATION
19	Inhibition of angiogenesis by arsenic trioxide <i>via</i> TSP-1-TGF-β1-CTGF–VEGF functional module in rheumatoid arthritis. Oncotarget, 2017, 8, 73529-73546.	1.8	33
20	IMPS-42CD70â€"A KEY DRIVER OF CHEMOKINE-MEDIATED IMMUNE SUPPRESSION AND INDICATOR OF NEGATIVE PROGNOSIS FOR GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v122.2-v122.	1.2	0
21	Long-term seizure outcome for international consensus classification of hippocampal sclerosis: A survival analysis. Seizure: the Journal of the British Epilepsy Association, 2015, 25, 141-146.	2.0	63
22	Long-term outcome of epilepsy surgery: A retrospective study in a population of 379 cases. Epilepsy Research, 2014, 108, 555-564.	1.6	13